This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Llovet JM, Hilgard P, de Oliveira AC, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med 2008; 13: 378-90. doi: 10.1056/NEJMoa0708857LlovetJMHilgardPde OliveiraACHilgardPGaneEBlancJFet alSorafenib in Advanced Hepatocellular CarcinomaN Engl J Med2008133789010.1056/NEJMoa0708857Open DOISearch in Google Scholar
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34. doi: 10.1016/S1470-2045(08)70285-7ChengALKangYKChenZTsaoCJQinSKimJSet alEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialLancet Oncol200910253410.1016/S1470-2045(08)70285-7Open DOISearch in Google Scholar
Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29(Suppl 4): iv238-55. doi: 10.1093/annonc/mdy308VogelACervantesAChauIDanieleBLlovetJMMeyerTet alHepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201829Suppl4iv2385510.1093/annonc/mdy308Open DOISearch in Google Scholar
Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol 2016; 65: 1140-7. doi: 10.1016/j. jhep.2016.07.020MarreroJAKudoMVenookAPYeSLBronowickiJPChenXPet alObservational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON studyJ Hepatol2016651140710.1016/j.jhep.2016.07.020Open DOISearch in Google Scholar
Lee S, Kim BK, Kim SU, Park SY, Kim JK, Lee HW, et al. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study: Sorafenib as a first-line therapy. J Gastroenterol Hepatol 2014; 29: 1463-9. doi: 10.1111/jgh.12542LeeSKimBKKimSUParkSYKimJKLeeHWet alClinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study: Sorafenib as a first-line therapyJ Gastroenterol Hepatol2014291463910.1111/jgh.12542Open DOISearch in Google Scholar
Doyle A, Marsh P, Gill R, Rodov M, Mohsen W, Varma P, et al. Sorafenib in the treatment of hepatocellular carcinoma: a multicentre real-world study. Scand J Gastroenterol 2016; 51: 979-85. doi: 10.3109/00365521.2016.1166518DoyleAMarshPGillRRodovMMohsenWVarmaPet alSorafenib in the treatment of hepatocellular carcinoma: a multicentre real-world studyScand J Gastroenterol2016519798510.3109/00365521.2016.1166518Open DOISearch in Google Scholar
Llovet LM, Bruix J. Management of HCC. Hepathology 2008; 48: 1312-27. doi: 10.1002/hep.22506.LlovetLMBruixJManagement of HCCHepathology20084813122710.1002/hep.22506Open DOISearch in Google Scholar
Forner A, Llovet LM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-55. doi: 10.1016/S0140-6736(11)61347-0FornerALlovetLMBruixJHepatocellular carcinomaLancet201237912455510.1016/S0140-6736(11)61347-0Open DOISearch in Google Scholar
